Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: J Immunol. 2011 Aug 10;187(6):2915–2922. doi: 10.4049/jimmunol.1000180

FIGURE 6.

FIGURE 6

Transferred Smarta cells do not produce IL-17A during diabetogenesis. Ly5.1+-allelically marked IL-17A eGFP reporter Smarta CD4 T cells were transferred on day -1 to LCMV-infected RIP-LCMV-GP mice (n=4 per time point). A In situ IL-17A production was assessed at indicated time points in spleen, pancreatic LN and pancreas by flow cytometry. Cells were stained fresh for surface markers and acquired fresh without prior in vitro restimulation, inhibition of protein secretion, cell fixation or permeabilization. Representative graphs are shown and displayed as IL-17A/eGFP versus Ly5.1 of the live CD4+CD8- lymphocyte gate. B,C Transferred Smarta cells do not produce IL-17 upon in vitro restimulation. Cells recovered as in A were restimulated in vitro in the presence of Brefeldin A with gp61-80 peptide (B) or PMA and ionomycin (C) before fixation, permeabilization and intracellular staining for IFNγ. Representative graphs (IFNγ versus IL-17A/eGFP) shown are gated on live Ly5.1+ (B6.SjL Smarta) CD4+CD8− lymphocytes. Frequencies <0.1% are rounded to zero.